Goals of asthma treatment: How high should we go?

European Respiratory Journal

Volumn 24, Issue 5, 2004, Pages 715-717

  Reddel, H K ^a  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; SALMETEROL;

ALGORITHM; ASTHMA; BODY WEIGHT; BRONCHUS HYPERREACTIVITY; CATARACT; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DRUG MEGADOSE; DYSPNEA; EDITORIAL; GLAUCOMA; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; OUTCOMES RESEARCH; PATIENT ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

ASTHMA; HUMANS;

EID: 8644233358     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.10104904     Document Type: Editorial

References (21)

1. Crofton J, Douglas A. Respiratory Diseases. 3rd Edn. Oxford, Blackwell Scientific, 1981.
2. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Resp Crit Care Med 2004; 170: 836-844.
3. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
4. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004; 59: 16-20.
5. Hawkins G, McMahon A, Twaddle S, Wood S, Ford I, Thomson N. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326: 1115.
6. Busse W, Koenig S, Oppenheimer J, et al. Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. J Allergy Clin Immunol 2003; 111: 57-65.
7. Green R, Brightling C, Woltmann G, Parker D, Wardlaw A, Pavord I. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879.
8. Green R, Brightling C, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
9. Leone FT, Fish JE, Szefler SJ, West SL, for the Expert Panel on Corticosteroid Use. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma. Chest 2003; 124: 2329-2340.
10. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223-225.
11. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990; 3: 1122-1127.
12. Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002; 57: 309-316.
13. Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide [erratum in Eur Respir J 2000; 16: 579]. Eur Respir J 2000; 16: 226-235.
14. GINA (Global initiative for asthma). Asthma management and prevention. Bethesda, MD, NHLBI, NIH, 1995. NIH Publication No. 96-3659A. www.ginasthma.com
15. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
16. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control [erratum in Lancet 1999; 353: 758]. Lancet 1999; 353: 364-369.
17. Grünberg K, Sharon RF, Sont JK, et al. Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Resp Crit Care Med 2001; 164: 1816-1822.
18. Osman LM, Mckenzie L, Cairns J, et al. Patient weighting of importance of asthma symptoms. Thorax 2001; S6: 138-142.
19. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
20. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113: 587-592.
21. Rabe KF, Adachi M, Lai CKW, et al. Worldwide severity and control of asthma in children and adults: The global Asthma Insights and Reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.